April 2023 in “Journal of the American Academy of Dermatology” Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
January 2021 in “Journal of Cancer Therapy” Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.
3 citations
,
January 2017 in “Journal of cardiovascular pharmacology” Re-evaluating minoxidil, reducing sodium intake, and addressing arteriolar hypertrophy can improve hypertension management.
22 citations
,
May 2011 in “European Journal of Cancer” The drug combination was safe and showed promise in treating advanced tumors.
8 citations
,
June 2016 in “Journal of Pharmacy Practice” Lisinopril, a heart medication, probably caused hair loss in a patient, which stopped after switching drugs.
August 2003 in “药物不良反应杂志” Combining finasteride and terazosin can cause severe allergic reactions.
24 citations
,
January 2017 in “International Journal of Trichology”
1 citations
,
January 2021 in “Research Square (Research Square)” Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
6 citations
,
January 1977 in “PubMed” Minoxidil effectively lowers severe high blood pressure long-term but isn't for routine use.
2 citations
,
June 2019 in “Boletín médico del Hospital Infantil de México” Tofacitinib treatment is used for teenagers with alopecia areata.
65 citations
,
February 2015 in “Neuro-Oncology” Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
October 2021 in “International journal of basic and clinical pharmacology” Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.
October 2019 in “European heart journal” Androgen-deprivation therapies increase the risk of certain heart conditions, but testosterone treatment may help.
3 citations
,
February 2019 in “Molecular genetics and metabolism” The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.
June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
51 citations
,
April 1982 in “Lancet” Most patients with hard-to-treat high blood pressure can be managed effectively with various treatments, but no single treatment is perfect.
March 2007 in “Journal of hypertension” Minoxidil effectively lowers blood pressure in patients with resistant hypertension.
January 2019 in “Actas urológicas españolas” Using mirabegron and solifenacin together is safe and more effective for treating overactive bladder than using either drug alone.
June 2017 in “Journal of The American Academy of Dermatology” Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.
20 citations
,
July 1990 in “Journal of the American Academy of Dermatology” Captopril may cause hair loss, as shown by a woman's hair regrowing after stopping the medication.
August 2025 in “Journal of the American Academy of Dermatology” January 2018 in “Haydarpaşa Numune Hastanesi tıp dergisi” Tamsulosin's sulfonamide group may contribute to floppy iris syndrome.
29 citations
,
January 2016 in “CNS drugs” Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.
6 citations
,
August 2017 in “Physiological Research” Setipiprant may reduce inflammation by blocking an enzyme called aldose reductase.
September 2012 in “DOAJ (DOAJ: Directory of Open Access Journals)” D-004 shows moderate antidepressant effects but is less effective than Sertraline and Imipramine.
January 2022 in “Drugs of Today”
728 citations
,
August 1996 in “The New England Journal of Medicine” Terazosin and finasteride effectively treat BPH, but combining them adds no extra benefit.
April 2011 in “Reactions Weekly”